Literature DB >> 10406949

A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation.

L Supino-Rosin1, A Yoshimura, H Altaratz, D Neumann.   

Abstract

The erythropoietin receptor (EPO-R) is the cellular target for erythropoietin (EPO), the primary hormone that mediates the proliferation of immature erythroblasts and their differentiation into mature erythrocytes. Unusual features of the EPO-R are its short half-life (t(1/2) 1-2 h), its degradation via multiple pathways and the fact that less than 1% of total cellular EPO-R molecules are found on the cell surface. The contribution of EPO-R structural determinants to the regulation of its intracellular metabolism is still unclear. The epidermal growth factor receptor (EGF-R), unlike the EPO-R, is efficiently transported to the cell surface and displays a much longer metabolic half-life. To determine which EPO-R cytosolic domains are involved in intracellular degradation, we studied chimeric receptor molecules constructed of EGF-R extracellular and transmembrane parts, linked to the full length or truncated cytosolic part of the EPO-R. The chimeras were expressed in transiently transfected COS 7 cells and stably expressed in Ba/F3 cells. Our experiments indicate that the cytosolic part of the EPO-R contains determinants that mark it for rapid degradation, in association with the endoplasmic reticulum (ER). This degradation was insensitive to brefeldin A and was inhibited by specific proteasomal inhibitors. A truncated EGF-R/EPO-R chimera containing only 50 amino acids of the EPO-R membrane-proximal cytosolic part was also rapidly degraded suggesting that these 50 amino acids are involved in receptor degradation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10406949     DOI: 10.1046/j.1432-1327.1999.00516.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  11 in total

Review 1.  Survival and proliferative roles of erythropoietin beyond the erythroid lineage.

Authors:  Constance Tom Noguchi; Li Wang; Heather M Rogers; Ruifeng Teng; Yi Jia
Journal:  Expert Rev Mol Med       Date:  2008-12-01       Impact factor: 5.600

2.  Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited.

Authors:  Sigrun R Hofmann; Albert Q Lam; Stephan Frank; Yong-Jie Zhou; Haydeé L Ramos; Yuka Kanno; Davide Agnello; Richard J Youle; John J O'Shea
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

3.  The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression.

Authors:  Josiane Ragimbeau; Elisabetta Dondi; Andrés Alcover; Pierre Eid; Gilles Uzé; Sandra Pellegrini
Journal:  EMBO J       Date:  2003-02-03       Impact factor: 11.598

4.  An extracellular region of the erythropoietin receptor of the subterranean blind mole rat Spalax enhances receptor maturation.

Authors:  Orly Ravid; Imad Shams; Nathalie Ben Califa; Eviatar Nevo; Aaron Avivi; Drorit Neumann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-27       Impact factor: 11.205

5.  Molecular kinetics of nerve growth factor receptor trafficking and activation.

Authors:  Jérôme Jullien; Vincent Guili; Louis F Reichardt; Brian B Rudkin
Journal:  J Biol Chem       Date:  2002-06-07       Impact factor: 5.157

6.  Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling.

Authors:  Pardeep Heir; Tharan Srikumar; George Bikopoulos; Severa Bunda; Betty P Poon; Jeffrey E Lee; Brian Raught; Michael Ohh
Journal:  J Biol Chem       Date:  2016-02-04       Impact factor: 5.157

7.  Protein tyrosine phosphatase 1B participates in the down-regulation of erythropoietin receptor signalling.

Authors:  Jacob Cohen; Liat Oren-Young; Ursula Klingmuller; Drorit Neumann
Journal:  Biochem J       Date:  2004-01-15       Impact factor: 3.857

8.  The effect of erythropoietin on normal and neoplastic cells.

Authors:  Steve Elliott; Angus M Sinclair
Journal:  Biologics       Date:  2012-06-27

9.  Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO).

Authors:  Sukyung Woo; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-18       Impact factor: 2.410

10.  Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells.

Authors:  A M Sinclair; N Rogers; L Busse; I Archibeque; W Brown; P D Kassner; J E V Watson; G E Arnold; K C Q Nguyen; S Powers; S Elliott
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.